4//SEC Filing
ORBIMED ADVISORS LLC 4
Accession 0000947871-25-001088
CIK 0002036042other
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 7:29 PM ET
Size
11.5 KB
Accession
0000947871-25-001088
Insider Transaction Report
Form 4
ORBIMED ADVISORS LLC
Director
Transactions
- Sale
Common Stock
2025-12-17$44.50/sh−900$40,050→ 3,595,986 total(indirect: See footnotes) - Sale
Common Stock
2025-12-18$44.49/sh−100$4,449→ 3,595,886 total(indirect: See footnotes) - Sale
Common Stock
2025-12-19$44.49/sh−875$38,929→ 3,595,011 total(indirect: See footnotes)
OrbiMed Capital GP VIII LLC
Director
Transactions
- Sale
Common Stock
2025-12-17$44.50/sh−900$40,050→ 3,595,986 total(indirect: See footnotes) - Sale
Common Stock
2025-12-18$44.49/sh−100$4,449→ 3,595,886 total(indirect: See footnotes) - Sale
Common Stock
2025-12-19$44.49/sh−875$38,929→ 3,595,011 total(indirect: See footnotes)
Footnotes (2)
- [F1]These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
- [F2]This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
Sionna Therapeutics, Inc.
CIK 0002036042
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001055951
Filing Metadata
- Form type
- 4
- Filed
- Dec 18, 7:00 PM ET
- Accepted
- Dec 19, 7:29 PM ET
- Size
- 11.5 KB